2023
Nicotine addiction: More than just dopamine
Kim K, Picciotto M. Nicotine addiction: More than just dopamine. Current Opinion In Neurobiology 2023, 83: 102797. PMID: 37832393, PMCID: PMC10842238, DOI: 10.1016/j.conb.2023.102797.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNicotine addictionImportant public health problemAnti-tobacco messagingNicotine-induced behaviorsPublic health problemReward-related behaviorsNovel glutamateDopaminergic mechanismsSmoking cessationNicotine reinforcementMesolimbic systemNicotine seekingRecent studiesTherapeutic targetNicotine aversionHealth problemsActive investigationAdditional pathwaysSex differencesNicotine vapingMolecular mechanismsWithdrawalAddictionPathwayMolecular basis
2022
Social and Adaptive Functioning in Tourette Syndrome
Sukhodolsky D, Kalvin C, Artukoğlu B, Eicher V, Leckman J. Social and Adaptive Functioning in Tourette Syndrome. 2022, 391-404. DOI: 10.1093/med/9780197543214.003.0023.Peer-Reviewed Original ResearchAdaptive functioningAttention-deficit/hyperactivity disorderTourette syndromeThorough clinical assessmentCo-occurring disordersHyperactivity disorderQuality of lifePsychosocial interventionsClinical assessmentBehavioral disordersSymptom severityFunctioningStandardized ratingsDisordersActive investigationImpairmentSyndromeSeverity
2017
MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics
Tilstam PV, Qi D, Leng L, Young L, Bucala R. MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics. Expert Opinion On Therapeutic Targets 2017, 21: 671-683. PMID: 28562118, PMCID: PMC6130320, DOI: 10.1080/14728222.2017.1336227.BooksConceptsMacrophage migration inhibitory factorMIF family membersCardiovascular diseaseFamily cytokinesTherapeutic opportunitiesIschemia-reperfusion injuryChemokine-like functionsMigration inhibitory factorNovel therapeutic opportunitiesPro-survival mediatorsFamily membersInflammatory pathogenesisMyocardial infarctionMyocardial ischemiaClinical studiesPleiotropic cytokineImmune systemInhibitory factorReceptor pathwayCytokinesDiseaseMIF-2Active investigationMIF familyClinical translationAntigen Discovery and Therapeutic Targeting in Hematologic Malignancies
Braun D, Wu C. Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. The Cancer Journal 2017, 23: 115-124. PMID: 28410299, PMCID: PMC5856170, DOI: 10.1097/ppo.0000000000000257.Peer-Reviewed Original ResearchConceptsHematologic malignanciesAntigen discoveryImmune-based therapiesStem cell transplantationNovel tumor antigensAdoptive cell therapyInvestigational immunotherapiesImmune therapyCancer vaccinesCell transplantationTreatment modalitiesTumor antigensAntitumor effectsTherapeutic targetingMalignancyMalignant cellsImmunotherapyCell therapyTherapyActive investigationTreatmentFurther investigationTransplantationVaccineAntigenAutocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma
Cadamuro M, Brivio S, Spirli C, Joplin RE, Strazzabosco M, Fabris L. Autocrine and Paracrine Mechanisms Promoting Chemoresistance in Cholangiocarcinoma. International Journal Of Molecular Sciences 2017, 18: 149. PMID: 28098760, PMCID: PMC5297782, DOI: 10.3390/ijms18010149.Peer-Reviewed Original Research
2014
Effect of aging on microRNAs and regulation of pathogen recognition receptors
Olivieri F, Procopio AD, Montgomery RR. Effect of aging on microRNAs and regulation of pathogen recognition receptors. Current Opinion In Immunology 2014, 29: 29-37. PMID: 24769423, PMCID: PMC4119513, DOI: 10.1016/j.coi.2014.03.006.Peer-Reviewed Original ResearchConceptsInnate immune recognitionImmune innate responseResolution of inflammationPathogen recognition receptorsTLR signalsUnderstanding of immunosenescenceProinflammatory responseImmune responseNF-κBInnate responseImmune recognitionRecognition receptorsActive investigationImmunosenescenceDownstream effectorsRecent studiesNegative regulatorSimilar regulatory activitiesResponseMiRNAsInflammationMicroRNAsAging-associated miRNAsVaccine
2013
Clinical Presentation in Diffuse Low-Grade Gliomas
Torres-Reveron J, Piepmeier J, Becker K. Clinical Presentation in Diffuse Low-Grade Gliomas. 2013, 179-188. DOI: 10.1007/978-1-4471-2213-5_12.Peer-Reviewed Original ResearchDiffuse low-grade gliomasLow-grade gliomasCommon presenting symptomHigh-grade lesionsPrimary brain tumorsStandard imaging modalityPresenting symptomHistopathological findingsClinical presentationTumor sizeNeurological syndromeAnaplastic transformationBrain tumorsMultimodal evaluationConventional imaging technologiesImaging modalitiesActive investigationTumorsGliomasNew advancesSeizuresSyndromeLesionsSymptoms
2012
New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come
Nicholas J, Morgan-Followell B, Pitt D, Racke MK, Boster A. New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. Journal Of Central Nervous System Disease 2012, 4: jcnsd.s6692. PMID: 23650470, PMCID: PMC3619700, DOI: 10.4137/jcnsd.s6692.Peer-Reviewed Original ResearchMultiple sclerosisRelapsing-remitting multiple sclerosisKey clinical trialsDisease-modifying therapiesMonoclonal antibody therapyIFN β-1aIFN-β-1bMS includingAvailable efficacyOral agentsGlatiramer acetateTreatment algorithmAntibody therapyClinical trialsPromising therapySafety dataNew therapiesTherapyNew FDATherapeutic landscapeActive investigationNatalizumabFingolimodSclerosisFDA
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply